Equities researchers at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Envista in a research report ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Officer of Insmed Inc. (NASDAQ:INSM), recently sold a significant amount of company stock amid the company's impressive 178% surge over the past year. According to a recent SEC filing, Flammer sold a ...

The company built a digital platform for medical professionals that can help them carry out telehealth appointments with ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...